Chemed Analyst Questions Reveal Segment Concerns in Q3 Earnings Call
Chemed Corporation’s third quarter performance presented a complex picture, marked by operational challenges across its VITAS and Roto-Rooter businesses, leading to a negative reaction from the market. Management, led by CEO Kevin McNamara, attributed the margin compression to increased costs stemming from elevated hospital-based admissions at VITAS, coupled with a shift towards paid leads in Roto-Rooter, which subsequently elevated expenses and impacted profitability. McNamara highlighted the stabilization in VITAS’s Medicare Cap exposure and noted a “high watermark” in hospital admission ratios, while also pointing to encouraging results from Roto-Rooter’s residential plumbing campaign. Chief Financial Officer Michael Witzeman described the quarter’s gross margin as “exactly in line with our guidance,” though he acknowledged that segment margins remain below long-term targets. The company reported revenue of $624.9 million, slightly ahead of analyst estimates of $626 million, representing year-over-year growth of 3.1%. Adjusted earnings per share (EPS) reached $5.27, a miss against analyst expectations of $5.37, reflecting an adjusted EBITDA of $109 million, also slightly below estimates of $113.9 million, with a margin of 17.4%. Adjusted EPS guidance for the full year stands at $22.15 at the midpoint. Operating Margin decreased to 12%, down from 15.2% in the same quarter of the previous year. Sales volumes increased by 2.5% year-over-year. The company’s market capitalization currently sits at $6.22 billion.
During the earnings call, analysts probed management for clarity on the path forward. Benjamin Hendrix of RBC Capital Markets questioned how management intended to bridge the Q3 results with full-year guidance, given the tracking of both segments below Street estimates. Witzeman responded by citing Q4 seasonality and anticipated margin improvements as the primary drivers behind the projected trajectory. Brian Tanquilut of Jefferies raised concerns regarding the sustainability of margin improvements, particularly within Roto-Rooter, and how increased marketing costs affect the company’s long-term business models. Witzeman explained that operational initiatives and lead generation efforts would offset margin pressure over time. Joanna Gajuk of Bank of America inquired about Roto-Rooter’s margin outlook, given the shift to paid leads and recent margin trends. Witzeman stated that while near-term pressures remain, management expects margins to trend back toward 25–26% with improved operational controls. Gajuk further investigated the drivers behind the sequential improvements in VITAS’s gross margin, attributing this to targeted efficiencies and cost management at the program level.
Looking ahead, analysts are focused on several key developments. The company’s analysts will be monitoring whether VITAS can sustain its hospital admission ratio and avoid Medicare Cap limitations in Florida, a critical risk factor. They will also be tracking the progress of margin recovery at Roto-Rooter amid higher marketing spend. Furthermore, the ramp-up of new program launches, such as the Pinellas County location, will be closely observed. Developments in lead generation effectiveness and operational improvements will be key indicators of the company’s overall business momentum. Chemed currently trades at $440.68, aligned with $439.05 just before the earnings release.
The market’s attention is increasingly directed toward potential investment opportunities. Following the April 2025 tariff bombshell, which triggered a massive market selloff, stocks have since staged an impressive recovery, leaving those who panicked sold on the sidelines. Investors can take advantage of this rebound by exploring a curated list of high-quality stocks. For instance, Nvidia has generated a market-beating return of 1,545% over the last five years (as of March 31st, 2025), and Tecnoglass has achieved a remarkable 1,754% five-year return. These stocks, along with others, represent compelling investment opportunities. StockStory is also actively growing, hiring equity analyst and marketing roles, and seeks passionate individuals to join its team.
